Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/8866
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Polat, Meltem | - |
dc.contributor.author | Kara, S.S. | - |
dc.date.accessioned | 2019-08-16T12:57:01Z | |
dc.date.available | 2019-08-16T12:57:01Z | |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1178-6973 | - |
dc.identifier.uri | https://hdl.handle.net/11499/8866 | - |
dc.identifier.uri | https://doi.org/10.2147/IDR.S148703 | - |
dc.description.abstract | Background: The rise in community-acquired urinary tract infections (UTIs) with extendedspectrum ß-lactamase (ESBL)-producing Escherichia coli strains raises the question of how to treat these infections effectively in pediatric outpatients. Amikacin has shown promising in vitro activity against ESBL-producing urinary isolates of E. coli; however, clinical data are limited. Objective: To investigate the clinical and microbiological outcomes of community-acquired lower UTIs caused by ESBL-producing E. coli treated with outpatient amikacin in children. Materials and methods: A retrospective cohort study was performed on pediatric patients aged ?2 to 18 years treated as outpatients with intramuscular amikacin (given at a dose of 15 mg/kg/day once daily) for community-acquired lower UTIs caused by ESBL-producing E. coli, between January 2015 and December 2016. Results: A total of 53 pediatric patients (38 females) were enrolled in this study. The median age was 4.7 years (range 3-12 years). All E. coli isolates were susceptible to amikacin with minimum inhibitory concentrations of ?4 mg/L. The median duration of amikacin treatment was 6 days (range 3-7 days). Favorable clinical and bacteriological responses were observed in 51 of 53 (96%) patients. Development of resistance during treatment with amikacin was seen in only 1 patient (2%), who failed to respond to amikacin treatment and developed acute pyelonephritis with bacteremia. Relapsed lower UTI after initial treatment response occurred in 1 patient (2%) 2 weeks after completion of amikacin treatment. All patients had normal serum creatinine values at baseline, and no significant nephrotoxicity or ototoxicity was observed in any of the patients. Conclusion: Our study suggests that once-daily intramuscular amikacin could be an alternative option for outpatient treatment of community-acquired lower UTIs caused by amikacinsusceptible ESBL-producing E. coli in pediatric patients with normal renal function, when there are no suitable oral antibiotics. © 2017 Polat and Kara. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Dove Medical Press Ltd. | en_US |
dc.relation.ispartof | Infection and Drug Resistance | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Amikacin | en_US |
dc.subject | Children | en_US |
dc.subject | Community-acquired urinary tract infections | en_US |
dc.subject | Escherichia coli | en_US |
dc.subject | Extended-spectrum ß-lactamase | en_US |
dc.subject | Outpatient | en_US |
dc.subject | amikacin | en_US |
dc.subject | acute pyelonephritis | en_US |
dc.subject | antibiotic sensitivity | en_US |
dc.subject | Article | en_US |
dc.subject | bacteremia | en_US |
dc.subject | child | en_US |
dc.subject | controlled study | en_US |
dc.subject | drug response | en_US |
dc.subject | drug treatment failure | en_US |
dc.subject | extended spectrum beta lactamase producing Escherichia coli | en_US |
dc.subject | female | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | minimum inhibitory concentration | en_US |
dc.subject | nonhuman | en_US |
dc.subject | outpatient | en_US |
dc.subject | preschool child | en_US |
dc.subject | relapse | en_US |
dc.subject | retrospective study | en_US |
dc.subject | school child | en_US |
dc.subject | treatment duration | en_US |
dc.subject | urinary tract infection | en_US |
dc.title | Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum ß-lactamase-producing Escherichia coli in children | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 10 | en_US |
dc.identifier.startpage | 393 | |
dc.identifier.startpage | 393 | en_US |
dc.identifier.endpage | 399 | en_US |
dc.authorid | 0000-0002-4608-1286 | - |
dc.identifier.doi | 10.2147/IDR.S148703 | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.pmid | 29138582 | en_US |
dc.identifier.scopus | 2-s2.0-85036584713 | en_US |
dc.identifier.wos | WOS:000414188000001 | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.owner | Pamukkale University | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.fulltext | With Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
intramuscular.pdf | 306.49 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
14
checked on Jun 29, 2024
WEB OF SCIENCETM
Citations
11
checked on Jul 10, 2024
Page view(s)
32
checked on May 27, 2024
Download(s)
4
checked on May 27, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.